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Background: Statin medications, used to prevent heart disease by reducing cholesterol, also reduce inflammation
and protect against oxidative damage. As inflammation and oxidative stress occur in depression, there is interest in
their potential to reduce depression risk. We investigated whether use of statin medications was associated with a
change in the risk of developing depression in a very large Swedish national cohort (n = 4,607,990).
Methods: National register data for adults ≥40yr was analyzed to obtain information about depression diagnoses
and prescriptions of statin medications between 2006 and 2008. Associations were tested using logistic regression.
Results: Use of any statin was shown to reduce the odds of depression by 8% compared to individuals not using
statin medications (OR = 0.92, 95% CI, 0.89-0.96; p < 0.001). Simvastatin had a protective effect (OR = 0.93, 95% CI,
0.89-0.97; p = 0.001), whereas atorvastatin was associated with increased risk of depression (OR = 1.11, 95% CI, 1.01-1.22;
p = 0.032). There was a stepwise decrease in odds ratio with increasing age (OR≥ 40 years = 0.95, OR≥ 50 years = 0.91,
OR≥ 60 years = 0.85, OR≥ 70 years = 0.81).
Conclusions: The use of any statin was associated with a reduction in risk of depression in individuals over the age of
40. Clarification of the strength of these protective effects, the clinical relevance of these effects and determination of
which statins are most effective is needed.
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Depression is an episodic condition with recurrence com-
mon across the lifespan [1-3], and a typical relapse rate of
between 50-70% depending on number of previous epi-
sodes [1]. An inflammatory model of depression has been
put forward in recent years, highlighting the role of
inflammatory, oxidative and nitrosative stress (IO&NS)
pathways in the development of depression and con-
ceptualizing depression within the spectrum of neuro-
progressive disorders [4,5]. Previous evidence supporting
this model has shown pro-inflammatory cytokines to be
increased in patients with depression [6], disease states
characterized by inflammation are often accompanied
by depressive illness [7,8], and patients exposed to pro-
inflammatory cytokines often report subsequent devel-
opment of depression [9]. Inflammatory responses are* Correspondence: jan.sundquist@med.lu.se
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unless otherwise stated.known to be accompanied by stimulation of IO&NS
pathways and the production of free radicals [4], which
can lead to oxidation and cell damage over time if not
regulated. There is parallel evidence that markers of
oxidative damage appear to be increased in patients di-
agnosed with depression [4], leading to the hypothesis
that agents targeting inflammation and IO&NS path-
ways may be effective in both treating and reducing
the risk of depression.
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitors, are commonly prescribed lipid-lowering
drugs used primarily in the treatment of high cholesterol
and cardio-vascular disease [10]. Evidence suggests that
statins may also have a neuroprotective quality [10], with
studies finding that statin use may be associated with a re-
duction in the incidence of dementia [11], Alzheimer’s
disease [12] and Parkinson’s disease [13]. Statins have also
been linked to possible neurocognitive effects [14]. It has
been hypothesized that the effects may be due to action atLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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duce oxidative stress [15,16] and to modulate inflammatory
responses [9,10].
Given the anti-inflammatory and anti-oxidative prop-
erties of statins, recent authors have hypothesized that
treatment with statins may have a protective effect on
the development of depression. This hypothesis is in
contrast to previous concerns that lowered cholesterol
levels could have a negative impact on mood and behav-
iour, with a number of early studies suggesting that low
levels of serum cholesterol (both naturally low and med-
ically lowered) were associated with lowered mood and
increased anger, hostility, aggression and possible sui-
cidal ideation [17]. Later studies investigating the effects
of statins specifically on mood have reported mixed
findings, with some suggesting an increased risk of
depression [18] and decrease in positive affect [19],
while others have found either no association between
statin use and mood disturbances [20-23], or that stains
in fact may protect against the risk of depression
[9,17,24-27]. A recent meta-analysis has supported the
latter conclusion [5]. Clarification of this association ap-
pears warranted, as confirmation that statin use is effective
in reducing the risk of subsequent depression could firstly
lend proof of principle support to the inflammatory model
of depression and may additionally lead to the develop-
ment of new treatment approaches. This data is addition-
ally important for clarifying the risk-benefit profile of
statins, given their status as one of the most widely
prescribed agents in medicine.
Aims of the study
The objective of the current study is to investigate the
relationship between use of statin medications and de-
velopment of depression in a large Swedish population
cohort. The effect of statin medications as a group as
well as the effect of individual statins will be examined.
Methods
Data sources
This study is based on anonymous data from census,
pharmacy, inpatient and outpatient registers for the entire
Swedish population aged 40 years and over. Individual-
level demographic information was obtained using na-
tional census data from 2005. Information regarding
prescription of statin medications was obtained from
the National Pharmacy Register, which is maintained
by the Swedish National Board of Health and Welfare.
This register contains a record of each medication pre-
scribed by a health care provider and dispensed by any
outpatient or inpatient pharmacy in Sweden from July 1,
2005. The medication data are classified according to the
Anatomical Therapeutic Chemical (ATC) System devel-
oped by the World Health Organization CollaboratingCentre for Drug Statistics Methodology. Data was ob-
tained for medications classified as lipid modifying
agents (code C10A), sub-classified as HMGCoA reduc-
tase inhibitors (statins, codes C10AA01 - 08).
Information regarding hospitalization for chronic ob-
structive pulmonary disease (COPD), alcohol depend-
ence and coronary heart disease (CHD) was obtained
from the Swedish National Inpatient Register (IPR), also
maintained by the Swedish National Board of Health
and Welfare. The IPR contains diagnostic and administrative
information regarding all somatic and psychiatric hospital
discharges in Sweden from 1987 and 1973 respectively.
Diagnoses in the IPR are classified according to the Inter-
national Classification of Disease (ICD) system developed
by the World Health Organization.
Study population
The study population consisted of all men and women over
the age of 40 identified as living in Sweden as of January 1,
2006. We excluded 11695 individuals who were identified
as having had a diagnosis of depression that preceded a
prescription of statin medication during the study period
(0.25%). A total of 4,607,990 individuals remained for inclu-
sion in the analysis. The study cohort was followed from
January 1, 2006 through December 31, 2008.
Outcome variable
The outcome of interest was a diagnosis of depression
(ICD-10 codes F30 - F39) between January 1, 2006 and
December 31, 2008, by any inpatient or outpatient health
care provider in Sweden and by initiation of treatment as
indicated by medication data (ATC codes N06A) during
the study period. Only the first diagnosis for an individual
during the study period was included.
Independent variables
The association of interest was prescription of a statin
medication dispensed at any outpatient or inpatient phar-
macy in Sweden during the study period. This variable was
evaluated for prescription of any statin, and by individual
statins (simvastatin, pravastatin, fluvastatin, atorvastatin,
rosuvastatin lovastatin and pitavastatin). Prescription of a
statin medication was taken as a proxy for statin use during
the study period, with the assumption made that individ-
uals receiving a prescription would proceed to take the
medication as prescribed.
Other independent variables included gender, age [divided
into 10-year categories (40–49 years, 50–59 years, 60–69
years, and over 70 years)], immigration status (born in
Sweden, or born outside of Sweden) and marital status
(grouped as married/cohabitating or unmarried/widowed/
divorced/single). Education was obtained and grouped as
completion of compulsory school or less (≤9 years), practical
high school or some theoretical high school (10-11 years),
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income was obtained from the Total Population Register
provided by Statistics Sweden. This information was used to
determine the distribution of family incomes in Sweden,
categorised into quartiles (low, middle low, middle high, and
high income). Region of residence was categorised as large
cities (with a population over 200 000, i.e. Stockholm,
Gothenburg and Malmö), Southern Sweden, and Northern
Sweden. Previous hospitalisation for chronic obstructive
pulmonary disease (COPD, ICD-10 code J40-49), which
was suspected to be an important prognostic factor for de-
pression as a proxy for smoking, was dichotomized into
yes or no. Previous hospitalisation for alcoholism and
related liver disease (ICD-10 codes F10 and K70) was
dichotomized into yes or no. Previous hospitalisation
for coronary heart disease (CHD, ICD-10 codes I20 - I25)
was also dichotomized into yes or no.Statistical analysis
The incidence rate for depression over the study period
was calculated for each variable separately by dividing
the number of diagnoses by the total number of individ-
uals in each category. The calculations were made strati-
fying by age, and the results then multiplied by the
relative proportions within each age group and added to-
gether to obtain the age-standardized incidence rates. As
the outcome of interest was a binary categorical variable,
logistic regression was used to estimate odds ratios (ORs)
and 95% confidence intervals (95% CI) to represent the
strength of association between use of a statin medication
(any statin and by individual statins, vs. no prescription of
statin medication) and subsequent diagnosis of depression
during the study period. Analyses were conducted un-
adjusted, age-adjusted, and then were adjusted for other
independent variables in order to account for confounding
(gender, marital status, immigration status, education, fam-
ily income, region of residence, and previous hospitalization
for COPD, alcohol dependence and related liver disease,
and CHD). Adjusted odds ratios for the association be-
tween use of statin medications and subsequent diagnosis
of depression were then compared across age groups (≥40
years, ≥50 years, ≥60 years, ≥70 years). It was decided a
priori that significance would be accepted at p < 0.05. All
analyses were carried out using Stata statistical software,
version 11.2 [28].Ethical considerations
Data from the registers utilised in this study were
linked using an anonymous, serial number version of
the personal identification number provided to all
Swedish residents, ensuring confidentiality of the data.
This study was approved by the Ethics Committee of
Lund University, Sweden.Results
All individuals 40 years of age and older living in Sweden
at the start of the study period, totaling 4,607,990 individ-
uals, were included in the analysis. The age range was
from 40 to 111 years of age, with a mean age of 60. Indi-
vidual characteristics of the cohort, including number of
depression diagnoses by independent variable and age-
adjusted incidence rates (p/1000 population) during the
study period are presented in Table 1. The age distribution
of the cohort was fairly even across the four age groups,
with slightly more in the 40-49 year (26.9%), and less in
the 60-69 year old category (22.4%). Most individuals
(46%) had completed 12 years of schooling or more.
Those born outside of Sweden accounted for almost 14%
of the total number, and approximately half the cohort
(49%) was residing in large cities at the start of the study
period.
During the study period, 804,832 prescriptions for sta-
tin medication were dispensed. Of these prescriptions,
approximately 70% were prescribed to individuals aged
60 years and over, with the proportion of total prescrip-
tions increasing by increasing age group. No prescrip-
tions for lovastatin or pitavastatin were recorded during
the study period, therefore they were excluded from the
analysis. Of the remaining statins, simvastatin was by far
the most widely prescribed, accounting for 83% of total
statin prescriptions (n = 665,932).
Being a woman, single, having 9 years or less of educa-
tion, and having a history of hospitalization for COPD, al-
coholism or ischemic heart disease were associated with
relatively higher rates of depression within the cohort
(Table 1).
Table 2 presents the unadjusted and adjusted ORs from
for the association between statin prescription and subse-
quent diagnosis of depression. Use of any statin medi-
cation reduced the odds of subsequently developing
depression by approximately 8% compared to individ-
uals who had not used statin medications (OR = 0.92,
95% CI, 0.89-0.96; p < 0.001). After adjusting for potential
confounding variables, this result was slightly attenuated
(OR = 0.95, 95% CI, 0.91-0.99; p = 0.016). Use of simva-
statin similarly was associated with a reduction in the odds
of developing depression (OR = 0.93, 95% CI, 0.89-
0.97; p = 0.001). Conversely, prescription of atorva-
statin was associated with an 11% increase in the odds
of developing depression (OR = 1.11, 95% CI, 1.01-
1.22; p = 0.032). The relationship between depression
and other individual statin medications was not found
to be significant.
As statins vary in how hydrophilic or lipophilic they
are, and since lipophilic agents have better brain pene-
trance, we were interested if agents that were lipophilic
or hydrophilic differed. Lipophilic agents when pooled
(OR 0.92, 95% CI, 0.88-0.96; p < 0.001) but not hydrophilic
Table 1 Individual characteristics, number of depression cases by independent variable, and age-standardized rates
(p/1000 population) for diagnosis of depression between 2006-2008 (n = 4,607,990)






40-49 1,238,099 26.9 5,607 4.53 4.38-4.62
50-59 1,190,481 25.8 5,048 4.24 4.08-4.32
60-69 1,033,816 22.4 3,886 3.76 3.68-3.92
70+ 1,145,594 24.9 5,751 5.02 4.87-5.13
Gender
Male 2,220,494 48.19 8,317 3.75 3.67-3.83
Female 2,387,496 51.81 11,975 4.99 4.90-5.08
Civil status
Married/cohabitating 2,498,864 54.23 7,456 3.05 2.98-3.12
Unmarried/widowed/divorced/single 2,109,126 45.77 12,836 6.09 5.98-6.20
Immigration
Born in Sweden 3,968,191 86.12 17,298 4.36 4.30-4.42
Born elsewhere 639,799 13.88 2,994 4.63 4.46-4.80
Education
Compulsory school or less (≤ 9yrs) 1,244,872 27.02 6,384 5.03 4.91-5.15
Practical high school or some
theoretical high school (10-11yrs)
1,243,067 26.98 5,841 4.76 4.64-4.88
Theoretical high school and/or
college (≥ 12yrs)
2,120,051 46.01 8,067 3.93 3.84-4.02
Income
Low income 1,018,845 22.11 5,161 5.08 4.94-5.22
Middle low income 1,219,372 26.46 7,421 6.15 6.01-6.29
Middle high income 1,151,642 24.99 4,589 3.99 3.87-4.11
High income 1,218,131 26.44 3,121 2.79 2.69-2.89
Hospitalisation for COPD
No 4,581,872 99.43 19,908 4.35 4.29-4.41
Yes 26,118 0.57 384 19.86 17.87-21.85
Hospitalisation for alcohol dependence
No 4,583,249 99.46 18,856 4.12 4.06-4.18
Yes 24,741 0.54 1,436 54.34 51.53-57.15
Hospitalisation for CHD
No 4,496,433 97.6 19,599 4.37 4.31-4.43
Yes 111,557 2.4 693 7.02 6.50-7.54
Region
Large cities 2,259,664 49.04 10,452 4.64 4.55-4.73
Southern 1,579,534 34.28 6,617 4.19 4.09-4.29
Northern 768,792 16.68 3,223 4.2 4.05-4.35
Statin prescriptions
Any statin 804,832 17.47 3,313 4.59 4.43-4.75
Simvastatin 665,932 14.45 2,707 4.45 4.28-4.62
Pravastatin 27,244 0.59 103 5.21 4.20-6.22
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Table 1 Individual characteristics, number of depression cases by independent variable, and age-standardized rates
(p/1000 population) for diagnosis of depression between 2006-2008 (n = 4,607,990) (Continued)
Fluvastatin 5,932 0.13 24 5.07 3.04-7.10
Atorvastatin 95,231 2.07 429 5.49 4.97-6.01
Rosuvastatin 10,493 0.23 50 5.11 3.69-6.53
IR = age-standardized incidence rate; CI = confidence interval.
COPD = chronic obstructive pulmonary disease.
CHD = coronary heart disease.
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reduction in risk for depression.
In Table 3 the results of multivariable logistic regression
for the association between statin medication and develop-
ment of depression, adjusted for all independent variables,
are presented by increasing age group. A significant step-
wise decrease in the odds of depression following statin
use, with increasing age was observed (OR ≥ 40 years =
0.95, p = 0.16; OR ≥ 50 years = 0.91, p < 0.001; OR ≥ 60
years = 0.85, p < 0.001; OR ≥ 70 years = 0.81, p < 0.001).Discussion
The results of this study suggest that use of any statin
medication is associated with a reduced risk of subse-
quent diagnosis of depression, decreasing the risk of de-
veloping depression by as much as 5% after adjusting for
possible confounders. Of the individual statins, simva-
statin, by far the most widely used agent, was associated
with a 7% reduction in the risk of developing depression,
whereas atorvastatin was associated with an 11% in-
crease in the risk of developing depression. Associations
were not significant for other individual statins, likely
due to the small numbers of depression cases found
amongst the less commonly prescribed statins. Further-
more, lipophilic agents but not hydrophilic agents were
associated with a reduction in risk of depression. There
was a stepwise decrease in risk of depression following
statin use with increasing age group, with the highestTable 2 Unadjusted and adjusted ORs from logistic regression
subsequent diagnosis of depression between 2006-2008 (n =
Unadjusted OR 95% CI p-value Age-adju
Statin prescriptions
Any statin 0.92 0.89-0.96 <0.001 0.9
Simvastatin 0.91 0.87-0.95 <0.001 0.9
Pravastatin 0.86 0.71-1.04 0.120 0.8
Fluvastatin 0.92 0.61-1.37 0.677 0.9
Atorvastatin 1.02 0.93-1.13 0.632 1.0
Rosuvastatin 1.08 0.82-1.43 0.578 1.1
CI = confidence interval; OR = odds ratio.
aThe model includes prescription of statin medication (any statin, and by individual
60-69, 70+), marital status, education (three levels), family income (quartiles), hosp
hospitalisation for coronary heart disease, and region (large cities, Southern, Nadjusted decrease in risk (approximately 20%) for those
aged 70 years and over.
These data are consistent with findings from a number
of previous smaller studies which have examined the re-
lationship between statin use and depression in both
population based and clinical samples, although to our
knowledge this is the largest study to date and the only
one to have utilised a national cohort. Feng et al. [25],
examined the relationship between statin use and de-
pressive symptoms in a population-based sample of
2804 community-dwelling adults aged 55 years and over.
They found a significant negative association between
statin use and depressive symptoms (OR = 0.71, 95% CI
0.52-0.97). Depressive symptoms in this study were de-
termined using a depression rating scale designed specif-
ically for older people, as opposed to register data.
Similarly, Pasco et al. [9] in a study of 386 population
based women aged over 50 years, found women taking
either statins or aspirin for at least 6 months were less
likely to develop de novo major depression as deter-
mined by a clinical interview, with an age-adjusted OR
for major depressive disorder of 0.15 (95% CI 0.03-0.65)
in the case-control component of the study, and a haz-
ard ratio of 0.2 (95% CI 0.04-0.85) for the retrospective
cohort analysis. In a prospective cohort study involving
965 outpatients with coronary heart disease, Otte et al.
[27] found statin use to be associated with both a 34%
decrease in risk of depressive symptoms at baseline com-
pared to non-statin use (OR = 0.66, 95% CI 0.45-0.98),for association between statin prescription and
4,607,990)
sted OR 95% CI p-value Adjusted ORa 95% CI p-value
2 0.88-0.95 <0.001 0.95 0.91-0.99 0.016
1 0.87-0.94 <0.001 0.93 0.89-0.97 0.001
5 0.70-1.03 0.090 0.90 0.74-1.09 0.268
1 0.61-1.36 0.643 0.98 0.65-1.46 0.914
3 0.94-0.97 0.507 1.11 1.01-1.22 0.032
2 0.84-1.47 0.443 1.21 0.92-1.60 0.177
statins) and the following variables as covariates: gender, age (40-49, 50-59,
italisation for cardio-pulmonary disease, hospitalisation for alcoholism,
orthern).
Table 3 Adjusted ORs from multivariable logistic regression for association between statin prescription and
subsequent diagnosis of depression between 2006-2008, by increasing age group (n = 4,607,990)
Age ≥40 yrs Age ≥50 yrs Age ≥60 yrs Age ≥70 yrs
ORa 95% CI p-value ORa 95% CI p-value ORa 95% CI p-value ORa 95% CI p-value
Statin prescriptions
Any statin 0.95 0.91-0.99 0.016 0.91 0.87-0.95 <0.001 0.85 0.81-0.89 <0.001 0.81 0.76-0.87 <0.001
Simvastatin 0.93 0.89-0.97 0.001 0.90 0.86-0.94 <0.001 0.85 0.81-0.90 <0.001 0.82 0.76-0.87 <0.001
Pravastatin 0.90 0.74-1.09 0.268 0.84 0.69-1.04 0.104 0.80 0.64-1.01 0.061 0.72 0.54-0.96 0.026
Fluvastatin 0.98 0.65-1.46 0.914 0.91 0.59-1.39 0.660 0.89 0.55-1.43 0.662 1.03 0.60-1.78 0.906
Atorvastatin 1.11 1.01-1.22 0.032 1.04 0.94-1.16 0.427 0.95 0.84-1.07 0.384 0.93 0.80-1.10 0.412
Rosuvastatin 1.21 0.92-1.60 0.177 1.18 0.88-1.60 0.274 1.10 0.75-1.60 0.635 1.21 0.71-2.04 0.485
CI = confidence interval; OR = odds ratio.
aThe model includes prescription of statin medication (any statin, and by individual statins) and the following variables as covariates: gender, age (40-49, 50-59,
60-69, 70+), marital status, education (three levels), family income (quartiles), hospitalisation for cardio-pulmonary disease, hospitalisation for alcoholism, hospitalisation
for coronary heart disease, and region (large cities, Southern, Northern).
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period (OR = 0.67, 95% CI 0.48-0.92).
In a prospective follow-up study of 193 patients hospi-
talised for a cardiac event, Stafford and Berk [24] utilised
data from clinical interviews and self-report rating scales
to examine the relationship between post-discharge sta-
tin use and later development of depression. They found
a 69% decrease in the risk of developing depression 3
month post discharge for those prescribed any statin
medication compared to no statin medication (OR =
0.31, 95% CI 0.097-0.972), and a 79% decrease in risk
after 9 months (OR = 0.21 95% CI 0.052-0.876). In an-
other study utilising a clinical sample, Young-Xu et al.
[17] found that among patients with coronary artery dis-
ease (n = 606), long-term statin use (4-7 years) was associ-
ated with a reduction in the risk of increased depression
scores (OR = 0.63, 95% CI 0.43-0.93). Longer length of
exposure was associated with a progressive reduction in
levels of depression, with the impact only being seen after
a minimum of one year of statin treatment. This associ-
ation with duration of statin use was also found by Yang
et al. [26]. Their analysis of data from a case-control study
of 94,441 primary health patients found a significantly
lower risk of first-episode depression for patients exposed
to statin therapy (OR = 0.4, 95% CI 0.2-0.9) compared with
those receiving either non-statin lipid lowering therapy or
no lipid lowering therapy. The association was stronger
for those who were exposed to statin therapy for a year or
more, as compared to those with less than a year of
exposure.
Contradictory findings have, however, been reported in
other studies. In a study of 1,070,706 patients discharged
on either statin therapy or no statin therapy from Swedish
hospitals following ischemic stroke, Asplund et al. [23]
found no difference in self-reported low mood or pre-
scription of antidepressants after 3 months. The inclusion
in this study of only ischemic stroke patients, the short
follow up period and the broader age range (18 years andover) may account for the findings. Feng et al. [29], in a
prospective observational study of 1,803 participants aged
55 and over found there was no difference in depressive
symptoms between users and non-users of statins after 1.5
years. Post-hoc analysis revealed statin use may be associ-
ated with a reduction in symptoms for women and an in-
crease in symptoms for men, however the evidence for
this was not conclusive.
A number of randomised control trials have compared
the effects of individual statins, including lovastatin [20,30],
pravastatin [21,30], and simvastatin [18,19,22] on psycho-
logical wellbeing, mood and/or depressive symptoms ver-
sus placebo. None of these studies found statin use to be
protective against depression or negative changes in well-
being or mood, with Hyyppa et al. [18] finding that use of
simvastatin was associated with an increase in depression
after 24 weeks in hypercholesterolemic men (n = 120).
Similarly, Morales et al. [19] reported use of simvastatin
and a decrease in self-reported positive affect in elderly
volunteers with raised serum cholesterol after 15 weeks
(n = 80). The relatively short follow-up periods and
small number of depressed patients in both these stud-
ies, coupled with differences in the characteristics of
the samples compared to the current study, limit their
generalisability and are likely to influence the differ-
ences in results.
Strengths of the study
Undoubtedly the greatest strength of this study was the
large sample size, which increases the validity of the re-
sults. The size of the cohort also allowed for individual
statins to be investigated separately, which a number of
previous studies have been unable to do due to smaller
sample sizes or as a result of an experimental study de-
sign [31]. This is important as there have been some
suggestions that certain statins have more or less of an
effect on mood than others, potentially as a result of their
hydrophilic or lipophilic properties [31]. While some of
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have sufficient identified depression diagnoses to provide
the required power to find significant associations, we
were able to show a significant negative association be-
tween use of simvastatin, the most widely used agent, and
subsequent development of depression, and a significant
positive association between use of atorvastatin and subse-
quent development of depression. Given the smaller num-
bers of individuals on atorvastatin, the power of the
analysis was less than that for simvastatin. As hypothe-
sised, benefits were seen for pooled lipophilic but not
hydrophilic statins. As both simvastatin and atorvastatin
are classified as lipophilic statins, lipophilicity does not ap-
pear a plausible explanation for their divergent effects.
Furthermore, the use of a national cohort reduces the
possibility of selection bias and increases the generalisability
of these results, as it comprises a representative and diverse
group of individuals across a range of socio-economic, eth-
nic, language, education and regional backgrounds. Conse-
quently these results may be generalisable beyond Sweden
to similarly aged citizens of other comparable high-income
countries, particularly the other Nordic countries. Use of
national patient and pharmacy records to obtain data could
also be regarded as a strength of the study, eliminating the
possibility of recall bias which can be a problem in studies
utilising self-report questionnaires to obtain data on past
medication use and depressive symptoms.
Limitations of the study
The main methodological limitation of this study, as with
any observation study, was the potential undermining of
internal validity due to unknown and unequally distributed
confounding factors across the groups being compared.
Many well-known potential confounders were adjusted for,
although it is possible that other unidentified confounders
(such as medications, physical co-morbidities or lifestyle
factors) have had an impact on the results. Body Mass
Index (BMI) in particular is known to be associated with
both depression and cardio-vascular conditions leading to
statin use, however data on BMI was not able to be ob-
tained using the available data sources for this study. His-
tory of hospitalisation for COPD and alcohol dependence
were used as proxies for smoking and alcohol use in an at-
tempt to control for lifestyle factors known to be associated
with depression and coronary heart disease, as such infor-
mation is not readily accessible through inpatient or out-
patient registers. While adjusting for such risk factors is
important to decrease the likelihood of confounding, these
are imperfect proxies and these indicators were only able
to identify a small minority of the total number of alcohol
users and smokers within the cohort, being those with the
most severe health consequences of their behaviour. Lack
of information on serum cholesterol level is also a limita-
tion of the study. It should be noted that while this study,conducted in a Swedish population cannot necessarily be
extrapolated to other populations [28], these results are
concordant with other published studies. Statins have clear
vascular effects, and as such may impact the risk for vascu-
lar depression, a particular factor in the elderly, and as such
their effects may not fully support the inflammatory hy-
pothesis [32]. Antidepressant effects in post-stroke depres-
sion are concordant with this potential [33].
Individuals with a previous diagnosis of depression
and other psychiatric disorders were not excluded from
this study, unlike some previous studies [9,19-21]. The
exclusion of these individuals may have decreased the
likelihood of confounding impacting on the results, how-
ever the high prevalence of mental disorders in the com-
munity would have resulted in the exclusion of a large
proportion of the cohort and furthermore would have
limited the generalisability of the findings [31].
The use of clinical diagnoses and prescription of anti-
depressant medication from patient registers to identify
cases of depression rather than clinical interviews or ques-
tionnaires may have resulted in an underestimation of the
true number of depression diagnoses during the study
period, especially amongst those not utilising health care
services on a regular basis (who would be less likely to be
identified and assessed for possible depression), or those
being treated solely with psychological and other non-
biological treatments. Due to the increased likelihood that
those individuals prescribed statins during the study
period were seen with some regularity by a health care
practitioner, it is possible that this could constitute a dif-
ferential information bias with the underestimation being
more prominent amongst those not on statin therapy. If
this were the case we could expect our results to be an
underestimate of the true association, pulling the results
away from the null hypothesis. It’s also possible that these
results would pull towards the null hypothesis.
Other limitations of the study were the lack of infor-
mation on statin dosage, adherence to treatment, and
duration of statin use. We have assumed that all those
collecting a prescription for a statin medication have in
fact taken the medication as prescribed, although it has
been estimated that 12-month adherence rates to statins
are around 60%, with the risk of non-adherence reducing
with increasing age [14,27]. This is a potential source of
non-differential information bias within the study due to
the likely overestimation in numbers exposed to statin
use amongst both those with and without a diagnosis of
depression; the likely effect is to under-estimate the
strength of the associations. Other studies have found an
association between increasing duration of statin use
and decreased risk of depression [17], and being unable
to control for that in this study may have impacted on the
results. Our findings suggesting increasing protection
against the risk of depression by increasing age group
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use in older patients and a higher percentage of use in
that population increasing power, however this cannot
be confirmed. It is possible that the impact of statins
would be different in younger cohorts.
This study cannot provide direct proof of the inflamma-
tory hypothesis of depression. At best, it is indirectly sup-
portive, given that statins have clear anti-inflammatory
properties, and that these results are broadly concordant
with the published literature showing a potential anti-
depressant effect of statin therapy. Definitive proof will
come from clinical trials of statins that are able to show
that the benefit of statins on mood are mediated by
changes in inflammatory biomarkers.
Conclusions
Our findings support the hypothesis that treatment with
statin medications reduces the risk of subsequent devel-
opment of depression. While the association for any
statin use was statistically significant, the strength of the
association for those aged 40 years and over was not
strong and therefore may not be clinically significant
when considering the implications of this finding. Many
of the methodological limitations of the study such as
reliance on clinical diagnosis and assumptions regarding
adherence risk biasing the study towards underestima-
tion of effects. This issue is further complicated by the
fact that our findings showed differences in the effects of
individual statins, with simvastatin appearing to have a
protective effect on the development of subsequent de-
pression and atorvastatin appearing to increase the risk of
depression. These results may go some way to explaining
why previous studies have failed to conclusively confirm
or refute the hypothesis that statin use may have an effect
on mood and depressive symptoms, as the vast majority
have either examined the effects of only one or two indi-
vidual statins, or conversely have included many statins
but only analysed the combined effect of the group. Fur-
ther research comparing the effects of individual statins
on depression seems warranted, although this would
require the inclusion of sufficient numbers in order to
ensure conclusive and accurate results.
If, as has been hypothesised previously, some statins are
indeed able to provide protection against depression through
their action on oxidative and inflammatory processes [9,10],
this may guide the development of novel biological treat-
ments and preventive strategies beyond conventional anti-
depressant medications, which may have overt public health
significance. Further research to confirm the strength of
these protective effects and to determine which statins are
most effective is needed.
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